This recombinant monoclonal antibody is developed as a research-grade biosimilar to ZG-033, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as CD137 or 4-1BB. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells, NK cells, and other immune cell populations. Upon binding its ligand 4-1BBL, TNFRSF9 delivers critical signals that enhance T cell proliferation, survival, and cytotoxic function while promoting memory T cell formation. This receptor plays a pivotal role in regulating immune responses and has significant implications in cancer immunotherapy, autoimmune diseases, and viral infections.
ZG-033 serves as the reference antibody for this biosimilar product, representing an important tool for investigating TNFRSF9-mediated immune regulation. This antibody is valuable for researchers studying T cell activation mechanisms, tumor immunology, and the development of immune checkpoint-based therapeutics. It supports investigations into costimulatory signaling pathways and the therapeutic potential of targeting TNFRSF9 in various disease contexts, including solid tumors and hematological malignancies.
Email: support@cusabio.com
Distributors Worldwide